Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gross Profit: 2013-2025

Historic Gross Profit for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $98.6 million.

  • Amphastar Pharmaceuticals' Gross Profit fell 3.23% to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $357.0 million, marking a year-over-year decrease of 6.86%. This contributed to the annual value of $373.9 million for FY2024, which is 6.47% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Gross Profit is $98.6 million, which was up 14.05% from $86.5 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Gross Profit high stood at $108.4 million for Q3 2023, and its period low was $44.9 million during Q1 2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Gross Profit had a median value of $90.1 million in 2024 and averaged $90.5 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Gross Profit surged by 85.27% in 2023 and then declined by 9.87% in 2024.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Gross Profit stood at $56.2 million in 2021, then grew by 26.56% to $71.2 million in 2022, then surged by 35.09% to $96.1 million in 2023, then declined by 9.87% to $86.6 million in 2024, then decreased by 3.23% to $98.6 million in 2025.
  • Its Gross Profit stands at $98.6 million for Q3 2025, versus $86.5 million for Q2 2025 and $85.3 million for Q1 2025.